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Abstract Relaxin is a naturally occurring peptide hor-
mone that plays a central role in the hemodynamic and
renovascular adaptive changes that occur during preg-
nancy. Triggering similar changes could potentially be
beneﬁcial in the treatment of patients with heart failure.
The effects of relaxin include the production of nitric
oxide, inhibition of endothelin, inhibition of angiotensin II,
production of VEGF, and production of matrix metallo-
proteinases. These effects lead to systemic and renal
vasodilation, increased arterial compliance, and other
vascular changes. The recognition of this has led to the
study of relaxin for the treatment of heart failure. An initial
pilot study has shown favorable hemodynamic effects in
patients with heart failure, including reduction in ventric-
ular ﬁlling pressures and increased cardiac output. The
ongoing RELAX-AHF clinical program is designed to
evaluate the effects of relaxin on the symptoms and out-
comes in a large group of patients admitted to hospital for
acute heart failure. This review will summarize both the
biology of relaxin and the data supporting its potential
efﬁcacy in human heart failure.
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Introduction
In 1926, Frederick Hisaw noted that serum from pregnant
rabbits and guinea pigs injected into virgin guinea pigs
resulted in relaxation of the pubic ligaments, and in 1930, a
speciﬁc peptide was isolated and called relaxin [26, 37].
Over 40 years later, these same investigators, working with
others, noted that relaxin had multiple other effects,
including signiﬁcant effects on vascular function [37];
reviewed by [24]. Since then, the cardiovascular and renal
effects of relaxin have been investigated with a growing
understanding of the molecular, cellular, physiologic, and
clinical roles for this molecule (reviewed in [6, 24]).
The current understanding of relaxin indicates that it
plays a central role in the hemodynamic and renovascular
adaptive changes that occur during pregnancy (reviewed in
[41]). Triggering similar changes could potentially be
beneﬁcial in the treatment of patients with heart failure.
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this therapeutic application. The data available to date
indicate that relaxin may be a ‘‘player in human heart
failure’’ [21, 22]. This review will summarize both the
biology of relaxin and the data supporting its potential
efﬁcacy in human heart failure.
Relaxin molecule
Relaxin, which is naturally produced by the corpus luteum
during the menstrual cycle and pregnancy in women and by
the prostate in men, is a 6-kDa peptide made up of 53
amino acids. The primary structure of this peptide is shown
in Fig. 1. Relaxin has structural similarities to insulin,
including its synthesis as a single-chain molecule that folds
and undergoes removal of a C-peptide to yield a 2-chain
molecule with conserved disulﬁde bonds. Relaxin and
insulin, however, have distinctly different receptors and
consistent with this, have non-overlapping biological
properties.
Human relaxin has been manufactured and the synthe-
sized molecule is identical in amino acid sequence to the
mature, naturally occurring human relaxin.
Cardiovascular molecular biology of relaxin
Recent advances have led to a preliminary understanding
of the biology of relaxin receptors in the vasculature.
Relaxin activity is initiated by binding to its cognate
receptor, LGR7 (or RXFP1), a G-protein coupled receptor
with a pKd of 9.26 [33]. LGR7 is a member of the leucine-
rich repeats containing G-protein coupled receptor family
(LGR) which are also known as relaxin family peptide
receptors (RXFP) [38]. There is limited information on the
location of relaxin receptors, but LGR7 is localized in
small renal, mesenteric, and thoracic aortae in mice and
rats of both sexes [48]. Relaxin binding sites have also been
detected in blood vessels from humans, as well as in cells
and tissues from the human heart [38]. LGR8 (or RXFP2),
a receptor closely related to LGR7, has a binding afﬁnity
*10-fold lower than LGR7, but may activate similar, but
not identical, signaling pathways [35]. LGR8 receptors
may be localized in tissues, including the vasculature, with
a distribution pattern similar to that of LGR7 [38]. These
data suggest that relaxin administered therapeutically could
engage these vascular receptors to directly mediate
hemodynamic changes.
Relaxin itself has also been detected in rat renal, mes-
enteric and thoracic aorta [48], and in human saphenous
vein, mammary artery and vessels in the skin [42].
Therefore, a vessel-derived relaxin ligand-receptor system
could also act locally to affect vascular function.
An important intracellular second messenger in relaxin
signaling is cAMP (Fig. 2). Binding of relaxin to its
receptor leads to activation of mitogen-activated protein
kinase (MAPK) [23, 59], as well as phosphoinositide-3-
kinase (PI3 K) [46], to induce increases in cAMP in target
cells. In other cells in which responses to relaxin have been
measured, only small, transient increases in cAMP [51]o r
MAPK pathway activation with no increases in cAMP [49]
have been described, indicating the existence of alternate
signaling pathways. Interestingly, signaling via the gluco-
corticoid receptor has also been described [23, 35].
Relaxin causes systemic and renal hemodynamic effects
indirectly. Nitric oxide [2, 3, 12] and the endothelin type B
receptor [7, 23] act as mediators of relaxin’s vasodilatory
effect. Matrix metalloproteinases (MMPs), stimulated by
relaxin, convert Big Endothelin to its bioactive form,
Endothelin1–32, and are required for relaxin-mediated
vasodilation [40]. Other potential mediators of relaxin’s
vasodilatory activity are atrial natriuretic peptide [56],
which is produced in the heart, and vascular endothelial
growth factor (VEGF) in the endometrium [50, 58].
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Fig. 1 Structure of native and manufactured human relaxin
Fig. 2 Proposed mechanism of relaxin-mediated vasodilation and
arterial compliance
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123Recent evidence of ‘‘negative cooperativity’’ of relaxin
binding kinetics [55] suggests that downstream events may
occur with a biphasic (U- or bell-shaped) dose response. In
concurrence, cAMP is induced with a bell-shaped dose
response curve [34]. Further downstream, other effects that
occur with biphasic dose response curves include stimu-
lation of MMP expression by isolated cells [57], relaxin-
induced systemic and renal hemodynamic responses in rats
[13, 17, 18], and changes in osmolality in rats [13].
The stimulation of multiple vascular signaling pathways
on the vascular system by relaxin may offer particular
advantages in the treatment of heart failure. One of the
possible limitations of prior vasodilator therapy has been
that single mediators of heart failure have been speciﬁcally
targeted, allowing induction of compensatory parallel
pathways involving other neurohormones, leading to either
loss of effect or the appearance of safety problems with
increasing time or dose. Since relaxin works indirectly
through multiple pathways with short- and long-term
effects on hemodynamics, it may be particularly well sui-
ted for therapeutic treatment of heart failure, with acute and
sustained effects, as well as a favorable beneﬁt-risk proﬁle.
Introduction to relaxin pharmacology
Naturally occurring relaxin possesses multiple systemic
and renal vasodilatory properties that mediate maternal
adjustments to the demands of pregnancy, as well as con-
nective tissue remodeling, and angiogenic properties.
During the ﬁrst trimester, coincident with the rise in cir-
culating relaxin levels, cardiac output and global arterial
compliance both rise, systemic vascular resistance falls,
and glomerular ﬁltration rate (GFR) and renal blood ﬂow
(RBF) both increase. Nonclinical models and data from
clinical trials indicate that relaxin is the circulating factor
responsible for these changes. These data, as well as
mechanisms of these actions, are summarized in the sec-
tions below.
Non-clinical pharmacology
In nonclinical pharmacology models, relaxin has been
shown to cause systemic and renal vasodilation [44, 47]
and increases in global arterial compliance.
Systemic vasodilation
In rat models, relaxin decreases systemic vascular resis-
tance (SVR) (see Fig. 3); [8] and stimulates greater
decreases in SVR, when baseline SVR is high [8]. The
decrease in SVR is accompanied by an increase in cardiac
output, primarily due to an increase in stroke volume [8].
Relaxin also inhibits the vasoconstrictive properties of two
principal mediators of vasoconstriction in heart failure,
endothelin and angiotensin II (see Fig. 4); [14, 15, 44].
Mesenteric vessels, as well as small renal vessels, from
relaxin-treated rats showed reduced myogenic reactivity,
compared with rats treated with vehicle [47]. Vessels from
the mesenteric artery, but not the portal vein, isolated from
relaxin-treated rats also showed blunted responses to
vasoconstrictor agents, including norepinephrine and
angiotensin II [44]. Relaxin has shown vasodilatory activ-
ity superior to acetylcholine or nitroprusside in isolated rat
and guinea pig hearts [3]. Relaxin also induced vasodila-
tion in isolated human resistance vessels when treated
ex vivo [27].
Renal vasodilation
During pregnancy, vasodilation occurs in the renal vascu-
lature causing maternal renal hemodynamic adjustments
that anticipate the increasing metabolic demands of the
fetus. GFR and RBF increase by *45% during the ﬁrst
trimester, compared to pre-pregnant or post-partum values
[16, 53]. Direct and indirect measurements on the kidney
have concluded that vasodilation of both afferent and
efferent renal arterioles occurs leading to no increase in
Fig. 3 Relaxin effect on systemic vascular resistance and cardiac
output in rats (from [17])
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123glomerular capillary pressure [4]. In pregnancy, the
increase in RBF exceeds that of the increase in GFR,
leading to a decrease in calculated ﬁltration fraction. The
increase in GFR is believed to be mostly due to the increase
in RBF. A large body of research in rodent models has
suggested that these hemodynamic adjustments are, in
large part, mediated by relaxin (reviewed in [39]).
The renal vasodilation that is observed during pregnancy
has been reproduced following exogenous relaxin infusion
in rats [14, 15]. GFR and effective renal plasma ﬂow
(ERPF) increased by 33% and 49% over baseline, respec-
tively, in both male and ovariectomized female rats treated
with relaxin and this effect occurred within 1–2 h of
infusion of relaxin [13]. The relaxin-induced renal vaso-
dilation and improved GFR were mediated by the
endothelial ETB receptor subtype, presumably on endo-
thelial cells [31] and nitric oxide (NO) [14, 15]. Because
concurrent administration of inhibitors of NO and the ETB
receptor to midterm pregnant rats produced no further
decline in renal function than either agent given alone, a
common vasodilatory pathway has been hypothesized [7].
Furthermore, because the results can be replicated using
isolated renal arteries using myogenic reactivity as a
bioassay for vasodilation, they indicate that relaxin acts
directly on the vessel and that the signaling required,
including induction of the MMPs, ET1–32 production
leading to ETB receptor activation, and NO production,
occur locally in the vessel (reviewed in [6]).
Arterial compliance
Activation of matrix metalloproteinases (MMPs) lead to
increases in arterial compliance [15, 57]. Relaxin, infused
for as short a period as 2–3 days in rats, has been shown to
increase global arterial compliance, coincident with an
increase in cardiac output and decrease in SVR [8] and
consistent with its role in pregnancy [17]. The increase in
compliance studied in an ex vivo model showed a relaxin-
mediated increase in compliance, independent of smooth
muscle-mediated changes in tone, suggesting that altera-
tions in the extracellular matrix of the vessel wall
contributed to increased compliance.
Prior human testing in non-heart failure conditions
Vasodilation in non-heart failure studies
Seven clinical trials evaluated the safety and efﬁcacy of
relaxin administered by continuous subcutaneous infusion
at doses ranging from 6–200 lg/kg/day for periods of
6 months and up to 1 year in a few subjects (Data on ﬁle,
Corthera Inc.). In these studies, 257 patients were treated
with relaxin and 124 patients received placebo. Relaxin
treatment of systemic sclerosis patients was associated with
statistically signiﬁcant decreases, within normal limits, of
systolic and diastolic blood pressure in clinical trials. The
decrease in systolic blood pressure was greater by *two-
fold in subjects, who were hypertensive (SBP[140 mm
Hg) upon entry into the trial, compared to the group as a
whole (Fig. 5). No cases of symptomatic hypotension were
reported in relaxin-treated subjects in any of the systemic
sclerosis trials.
Renal function in healthy volunteers
In a physician-sponsored open-label research study of renal
function in normal volunteers conducted in Great Britain,
11 healthy male and female subjects were dosed with an IV
infusion of relaxin at 0.5–2.0 lg/kg/h, targeting pregnancy
serum concentrations, for 5 h [54]. GFR and RBF were
measured using inulin and PAH, respectively, according to
established methods. RBF increased by 43% but an
increase in GFR was not detected (see Table 1). The
ﬁnding that GFR was unaffected by relaxin is at odds with
nonclinical and clinical data indicating that relaxin
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Fig. 4 Relaxin reverses the effects of angiotensin II on hemodynamic
parameters in rats (adapted from [18])
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123increases GFR. It is possible that in this particular study, in
healthy volunteers, the dose of relaxin, the short period of
infusion, the volume status of the subjects, renal autoreg-
ulatory responses present in these normal subjects, or all of
those, played a role in circumventing a concurrent increase
in GFR. Relaxin also showed a modest natriuretic effect in
this study.
Renal function in non-heart failure studies
In the systemic sclerosis studies described above, relaxin
administration to subjects with systemic sclerosis was
associated with statistically signiﬁcant increases in pre-
dicted creatinine clearance over the 6 month course of
infusion (see Fig. 6); [25]; Data on ﬁle, Corthera Inc.). In
support of these results, serum creatinine, uric acid and
BUN levels were also decreased in these subjects. These
ﬁndings suggest that relaxin mediates increases in renal
function in humans.
Relaxin role in acute heart failure
The demonstrated effects of relaxin suggest that it may be
therapeutic in clinical settings where reductions in systemic
vascular resistance and improved renal blood ﬂow may be
beneﬁcial. The ADHERE and OPTIMIZE registries have
conﬁrmed on a large scale earlier observations that a sub-
stantially higher proportion of acute heart failure events
than was previously recognized are associated with ele-
vated blood pressure, most probably induced by
vasoconstriction and vasomotor nephropathy, or renal
vasoconstriction [1, 9, 32]. These symptoms may be
mediated by abnormal activation of the Renin-Angioten-
sin-Aldosterone System (RAAS), as well as of endothelin.
These patients represent the majority of patients with acute
heart failure and in some recent classiﬁcations have been
designated as having acute vascular failure or acute car-
diovascular (hypertensive) failure, in contrast to those with
acute decompensated (cardiac) failure [1, 10, 11, 45].
In addition, decreased renal blood ﬂow has been rec-
ognized as a major contributing factor to the renal
dysfunction that often accompanies acute heart failure [29,
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Table 1 Hemodynamic measurements before and after 4 h intrave-
nous infusion of relaxin in healthy human volunteers (adapted from
[54])
Parameter
a Baseline
b Relaxin
b
RPF (ml/min/1.73 m
2) 983 ± 133 1403 ± 165
c
GFR (ml/min/1.73 m
2) 117.7 ± 9.7 115.6 ± 7.8
MAP (mmHg) 114.7 ± 1.7 117.0 ± 3.0
PR (per min) 68 ± 1.8 67 ± 1.9
a RFP Renal plasma ﬂow; GFR Glomerular ﬁltration rate; MAP,
Mean arterial pressure, PR Pulse rate
b Data are presented as means ± SEM
c P\0.0001 baseline vs. relaxin
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12330, 43]. The degree of renal dysfunction is an important
prognostic factor for these patients [19, 52].
Potential mediators of this clinical syndrome include
activation of the RAAS, sympathetic nervous system, and
endothelin systems, as well as resistance to or failure of
counter-regulatory systems such as the natriuretic peptides
[9, 32].
In numerous nonclinical studies, relaxin has demon-
strated the ability to prevent or reverse the effects of the
neurohormones angiotensin II and endothelin. Acute infu-
sion of relaxin restored cardiac output, systemic vascular
resistance, and arterial compliance that were dysregulated
by infusion of angiotensin II in rats [18]. In isolated rat
aorta and mesenteric artery, relaxin pretreatment mitigated
the maximum contractile response to endothelin-1 by
*40% [23]. In rat studies, renal vasoconstriction induced
by angiotensin II, measured as decreases in GFR and RBF,
was reversed by infusion of relaxin [14]. In vitro, relaxin
also antagonized the effect of angiotensin II on increased
collagen deposition and proliferation in rat cardiac ﬁbro-
blasts [51], potentially by inhibition of the Smad
transcription factors required for extracellular matrix syn-
thesis [36].
Gene expression for relaxin and the relaxin receptor has
been detected in rat renal, mesenteric and thoracic aorta
[48], and in human saphenous vein, mammary artery, and
vessels in the skin [42]. These data suggest that there is
likely a vessel-derived relaxin ligand-receptor system that
can act locally to affect vascular function in humans.
Perhaps more importantly, the presence of relaxin receptors
in blood vessels strongly suggests that relaxin can engage
these receptors when given therapeutically. Relaxin’s va-
sodilatory activity has been attributed to NO acting as the
ultimate effector molecule [2, 14, 23], and it is also likely
that vasodilation is mediated via the endothelial endothelin
type B receptor.
Relaxin gene expression has been shown to be upregu-
lated in atria and ventricles from patients with heart failure,
compared to normal subjects [21, 22]. Elevated left ven-
tricular end-diastolic pressure in isolated rat hearts
stimulated relaxin gene expression, providing a possible
mechanism for the ﬁnding of enhanced relaxin expression
in ventricles from heart failure patients. These increases
may be reﬂected in increased serum relaxin in patients with
compensated heart failure [21, 22, 28]. These elevated
levels, though modest (8–16 pg/ml and 11–644 pg/ml in
CHF patients in the two cited studies; B2 pg/ml in control
subjects), compared to the 1000 pg/ml levels attained in
pregnant women, suggest compensatory upregulation of
relaxin in patients with heart failure. Relaxin did not appear
to be prognostic for outcome [28].
Since relaxin can decrease SVR, allowing increased
cardiac output, and can also improve or preserve renal
perfusion, it may be ideally suited for the treatment of
patients with heart failure, and in particular, patients with
acute vascular failure. In addition, relaxin-mediated
increases in arterial compliance, in conjunction with
vasodilation, may lead to improvements in both steady and
pulsatile arterial load components of arterial mechanics
[39], making it a unique potential therapeutic in heart
failure.
Phase 1 heart failure study
Relaxin in compensated CHF
A single site, open-label study of relaxin in patients with
compensated CHF has been completed at the Charite
Hospital in Germany [20]. This was a safety and dose-
ﬁnding study of intravenous relaxin given for 24 h at doses
ranging from 10 to 960 lg/kg/day. Pharmacodynamic
dose-response parameters (serial hemodynamic measure-
ments using pulmonary artery and radial artery catheters
and serial renal chemistry parameters) were evaluated to
deﬁne relaxin doses for further study.
The study enrolled 16 subjects with compensated CHF,
NYHA Class II–III due to ischemic heart disease, hyper-
tensive heart disease, or dilated cardiomyopathy with left
ventricular ejection fraction \35%, pulmonary capillary
wedge pressure (PCWP) C 16 mmHg and cardiac index
(CI) B 2.5 l/min/m
2. All 16 subjects completed dosing and
the Day 9 follow-up visit. Relaxin was safe and well-tol-
erated in all subjects.
Trends in improvement in a number of hemodynamic
parameters were observed during dosing and for several
hours thereafter. Doses of relaxin in the range of 10–
100 lg/kg/day appeared to have a more pronounced effect
than higher doses on right atrial pressure, pulmonary artery
pressure, PCWP and NT-pro-BNP, while higher doses in
the range of 240–960 lg/kg/day tended to have a greater
effect on CI (see Fig. 7). Values for systemic vascular
resistance decreased at all doses. No consistent changes in
heart rate or blood pressure were observed either during or
post-dosing.
The different dose responses observed for the hemody-
namic parameters may be explained by imbalances in
baseline hemodynamic status of the dose groups or may be
due to random variability in a small pilot study. However,
certain biological effects of relaxin are known to follow a
U-shaped dose-response curve [13, 18, 55, 57]. Alterna-
tively, counter-regulatory neurohormonal mechanisms may
have been stimulated at higher relaxin doses, thus over-
powering the salutary responses observed at the lower
doses. An intriguing alternative explanation may be that
doses in the lower range produce more venous
326 Heart Fail Rev (2009) 14:321–329
123vasodilation, (decrease in PCWP without change in CO/CI)
while higher doses may produce more arterial vasodilation.
Additional well-controlled hemodynamic studies will be
required to provide further insight into this pattern.
Serum markers of renal function reﬂected the improve-
ment in kidney function mediated by relaxin, i.e., decreases
in creatinine, uric acid, and BUN were observed during
dosing, presumably due to renal vasodilation. Small
increases in creatinine and BUN above baseline were
observed transiently at Day 9 post-dosing in the 960 lg/kg/
day relaxin dose group. Although these increases were not
associated with clinical signiﬁcance, it is possible that these
observations may represent nascent dose limiting toxicity
duetocounter-regulatorymechanisms(rebound).Hence,the
dose of 960 lg/kg/day was regarded as the maximally tol-
erated dose of IV relaxin in these patients with heart failure.
Phase 2/3 therapeutic heart failure studies
As noted above, a substantially higher proportion of
patients with acute heart failure than was previously rec-
ognized have elevated blood pressure at the time of
presentation, so called acute vascular failure. Renal dys-
function is a common co-morbidity and major predictor of
poor outcomes in all patients with acute heart failure, and
appears to be particularly common in patients with acute
vascular failure compared to those with other presentations
[5]. As of yet, no therapy has been demonstrated conclu-
sively to improve symptoms or renal function in this group
of patients. The current understanding of the hemodynamic
and renovascular effects of relaxin, as well as the encour-
aging results from the evaluation of relaxin in patients with
compensated heart failure, supported the investigation of
the use of relaxin as a therapeutic agent for the treatment of
patients with acute vascular failure. The RELAX-AHF
study has been undertaken to evaluate the effects of relaxin
therapy on symptoms, signs, and outcomes in these
patients.
RELAX-AHF is a multicenter, placebo-controlled,
double-blind, randomized, international trial assessing the
effects of intravenous relaxin in patients hospitalized with
acute heart failure (AHF). The RELAX-AHF trial includes
patients aged[18 years, hospitalized for AHF (deﬁned as
moderate or marked dyspnea, pulmonary congestion on
chest x-ray and elevated BNP), baseline systolic blood
pressure [125 mmHg, impaired renal function (estimated
creatinine clearance of 30–75 ml/min/1.73 m
2 by simpli-
ﬁed Modiﬁcation of Diet in Renal Disease formula).
Eligible patients will have received intravenous furosemide
and are randomized within 16 h of presentation. Endpoints
will include serial assessment of dyspnea using Visual
Analog Scale and 7-point Likert Scale. In addition, in-
hospital medication use, heart failure signs and symptoms,
weight loss, incidence of worsening heart failure, and the
length of hospital stay will be assessed. Serum creatinine
will be assessed serially until Day 14 to assess renal
function. After discharge and until Day 180, mortality and
cardiorenal rehospitalizations will be recorded.
A multicenter, international pilot study, Pre-RELAX-
AHF, has recently been conducted to determine the optimal
dose of relaxin to test in the main study, RELAX-AHF. A
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123total of 234 patients were randomized in the pilot study to
receive intravenous placebo or relaxin at doses of 10, 30,
100, and 250 ug/kg/d for 48 h.
Future directions
The naturally occurring peptide hormone relaxin holds
promise as a novel pleiotropic vasodilator for the treatment
of patients with acute heart failure and preserved or ele-
vated blood pressure (acute vascular failure). The effects of
relaxin include the production of nitric oxide, inhibition of
endothelin, inhibition of angiotensin II, production of
VEGF, and production of MMPs. These multiple mecha-
nisms by which relaxin causes systemic and renal
vasodilation, increased arterial compliance and other vas-
cular changes may prove beneﬁcial in these patients.
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